Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2023 Q2- Text added to 2023 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
AACR, accelerate, AG, American, Ankara, announced, Baptist, Biology, Bioscience, boost, Box, California, Carolina, Cellular, Center, cGMP, comprising, Conference, DNA, dose, Duarte, eligible, encoding, escape, eventual, expansion, Forest, Fred, Glycoprotein, Good, GP, growth, HIV, Hope, Hutchinson, impairment, implementing, joint, journal, Keystone, line, Master, Matrix, Medical, modified, Molecular, Multivalent, MVA, North, observation, October, Omicron, open, original, Plasmodium, portfolio, priming, ProBioGen, prophylactically, Protein, published, Replication, response, Reston, Salem, scalable, Seattle, single, site, Society, strain, structural, suspension, Symposia, Ta, titled, Trademark, treat, Vaccina, vaccinia, Vaccinology, validate, variant, variation, versatility, viral, Wake, Washington, Winston, Worcester, Wuhan
Removed:
direct
Valuein 2023 Q2 filing- Value in 2023 Q3 filing
Original filings
Filing view